Member Info for fatprofits

As your post was removed, yes they do.

* 12.815

Just taken 1281.5 - luck to holders.

That would have been Toff.

TA not my area at all - I guessestimate at best.

* net debt, debt and more debt.

That's your answer.

AZN have optionality with highly rated shares that GSK (currently)
do not have.

Given GSK re the wider UKX today, I'm not particularly hopeful!.

I've made a few quid.

Will be out and hopefully back lower (having allowed for the XD).

Take a look at the recent RNS re the size of Emma and Hal's
nil paid options.

FX increasingly weighing atm unfortunately.

Is just fantastic .

We could not hope for much better.

Risk/reward now looking highly favourable here imv.

I give very few Strong Buys on LSE,

however I'm increasingly convinced there is Upside for Unilever.

Please note this is IMV only, please DYOR as always.

gulf, may I suggest it is worth reading the FY statement in
full re the dividend.

If you want more detail the payout is addressed in the analyst Q&A
on the FY conference call.

The Covid-19 vaccine hype train has now been removed from the AZN SP.

Currently trading at the start of January 2020 levels, pre pandemic.

If the Alexion acquisition completes we are hopefully looking at multi

year double digit esrnings growth.

To be fair both the shares in issue and AZN net debt increases by a significant amount.

Because AZN are issuing their more highly rated shares to buy Alexion,

the acquisition will hopefully be nicely EPS accretive and cash flow should

see net debt fall quickly.

I thought AZN might have dipped below £70 short term, however buyers

appeared to come back in force yesterday.

Hopefully AZN can successfully develop a vaccine which targets the SA

variant, however this is not relevant to the SP imv.

papucel, with respect you appear to be lookimg for "definte" answers
where they do not exist.

No matter how well informed someone is on the sector or even on
GSK specifically, everyone can get it wrong

Investment is not a scientific experiment where variables
can be controlled. Inherent risk is the price you pay for "equity" returns.
If you have an overweight position in one stock returns are more
likely to deviate from wider benchmarks - sometimes dramatically so.

Good fortune with your holdings.

.

Goodness I'm not the one to ask!,
but flattered that you think so.

I hope so, but I'm afraid I don't know.

Given the UK macro data earlier today, hoped
we might get a little support, that appears faltering atm.

That's a good point!.

As mentioned on the ULVR board, short interest is not really something
I focus on.

Appreciate some find it a highly charged area and have strong views.

It is a very different world indeed.

I would not mind my youth and good looks back for a weekend,

but there is No way I would want to be starting out again now.

I would never encourage any one to use margin.

If someone is worried about a stock then they may be holding too many.

That's not a comment directed at holding GSK, I'm talking in very general terms only.

It's making holders look like an ass atm ).